Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer-Reference-Cited by-同舟云学术

Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer

Published:2020-10-01 Issue:10 Volume:6 Page:1598
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Tolaney Sara M.¹,Barroso-Sousa Romualdo¹²,Keenan Tanya¹³,Li Tianyu⁴,Trippa Lorenzo⁴,Vaz-Luis Ines⁵,Wulf Gerburg⁶,Spring Laura⁷,Sinclair Natalie Faye¹,Andrews Chelsea¹,Pittenger Jessica¹,Richardson Edward T.⁸,Dillon Deborah⁸,Lin Nancy U.¹,Overmoyer Beth¹,Partridge Ann H.¹,Van Allen Eliezer¹³,Mittendorf Elizabeth A.⁹¹⁰,Winer Eric P.¹,Krop Ian E.¹

Affiliation:

1. Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts

2. Oncology Center, Hospital Sírio-Libanês, Brasília, Brazil

3. Broad Institute of MIT and Harvard, Boston, Massachusetts

4. Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts

5. Unit Inserm 981, Gustave Roussy, Villejuif, France

6. Medical Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts

7. Medical Oncology, Massachusetts General Hospital, Boston

8. Pathology, Brigham and Women’s Hospital, Boston, Massachusetts

9. Division of Breast Surgery, Department of Surgery, Brigham and Women’s Hospital, Boston, Massachusetts

10. Breast Oncology Program, Dana-Farber/Brigham and Women’s Cancer Center, Boston, Massachusetts

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2769923/jamaoncology_tolaney_2020_oi_200060_1619718159.01566.pdf

Reference24 articles.

1. PD-L1 expression in triple-negative breast cancer.;Mittendorf;Cancer Immunol Res,2014

2. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.;Denkert;Lancet Oncol,2018

3. The genomic landscape of breast cancer and its interaction with host immunity.;Luen;Breast,2016

4. Safety and antitumor activity of pembrolizumab in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer.;Rugo;Clin Cancer Res,2018

5. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN solid tumor study.;Dirix;Breast Cancer Res Treat,2018

Cited by 100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrative analysis of pan-cancer single-cell data reveals a tumor ecosystem subtype predicting immunotherapy response;npj Precision Oncology;2024-09-15

2. Progesterone receptor impairs immune respond and down-regulates sensitivity to anti-LAG3 in breast cancer;Translational Research;2024-09

3. Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer;Cancer Immunology, Immunotherapy;2024-08-06

4. Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives;Signal Transduction and Targeted Therapy;2024-08-02

5. Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer;JNCI: Journal of the National Cancer Institute;2024-07-31